Correlation between RUNX3 expression of Colorectal Cancer and Its Clinical Characteristics: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 DEJi ^1,2 , GUOTian-jiao ¹ , SUChang ¹ , ZHULin-lin ¹ , YANGJin-lin ¹ ,  WANGYi-ping ¹

1. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, China;
2. Tibetan Hospital of Tibet Autonomous Region, Lhasa 850000, China;

Corresponding author：

WANGYi-ping, Email: wyplm2012@163.com

Keywords：

RUNX3; Colorectal cancer; Systematic review; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20140135

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the correlation between RUNX3 expression of colorectal cancer and its clinical characteristics. Methods Databases including PubMed, The Cochrane Library (Issue 9, 2013), EMbase, MEDLINE (Ovid), CNKI, VIP, WanFang Data and CBM were searched for collecting published international and domestic case-control studies on the correlation between RUNX3 expression of colorectal cancer and its clinical characteristics from the date of their establishment to October 1st, 2013. Two reviewers screened literature according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of the included studies. Then, meta-analysis was performed using RevMan 5.2 software. Results A total of 7 case-control studies were included involving 804 cases in total (521 cases in colorectal cancer group and 383 cases in control group). The results of meta-analysis showed that, RUNX3 expression was lower in the colorectal cancer group than in the normal control group (OR=0.05, 95%CI 0.03 to 0.08, P < 0.000 01); higher in the moderately/highly-differentiated group than in the poorly differentiated group (OR=4.77, 95%CI 2.88 to 7.90, P < 0.000 01); higher in colorectal cancer with invasion depth on T₁-T₂ stage than in that on T₃-T₄ stage (OR=8.13, 95%CI 4.15 to 15.92, P < 0.000 01); and lower in the colorectal cancer accompanied with lymph node metastasis than that without lymph node metastasis (OR=0.23, 95%CI 0.14 to 0.36, P < 0.000 01), all with significant differences. No significant difference was found in RUNX3 expression between groups by age, sex and tumour location. Conclusion RUNX3 expression is notably correlated to colorectal cancer and its clinical characteristics. Due to the quantity and quality limitation of the included studies, the above conclusion still needs to be further proved by performing more high quality studies.

Citation： DEJi, GUOTian-jiao, SUChang, ZHULin-lin, YANGJin-lin, WANGYi-ping. Correlation between RUNX3 expression of Colorectal Cancer and Its Clinical Characteristics: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2014, 14(7): 806-812. doi: 10.7507/1672-2531.20140135 Copy

1.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA-Cancer J Clin, 2009, 59(4):225-249.
2.	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA-Cancer J Clin, 2011, 61(2):69-90.
3.	陈光侠, 何晓华, 陆敬华, 等.舒林酸对结肠癌SW1116细胞生长的影响.浙江临床医学, 2010, 12(1):3-6.
4.	Lee Y M. Control of RUNX3 by histone methyltransferases. J Cell Biochem, 2011, 112(2):394-400.
5.	Bosman F T, Cameiro F, Hruban R H, et al. World health organization classification of tumours of the digestive system. Lyon:IARC Press, 2010.
6.	Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews:Beyond the Basics. 2000.
7.	叶盛前, 叶菲, 金银姬, 等. RUNX3蛋白与Bcl-2家族蛋白在结肠癌中的表达及其意义.肿瘤学杂志, 2011, 17(12):893-896.
8.	汪砥, 钟美佐. RUNX3蛋白在大肠癌中的表达及其与临床化疗疗效关系探讨.肿瘤药学, 2011, 1(3):183-184.
9.	王殉, 王明林, 胡义奎. RUNX3蛋白在人结直肠癌中的表达及其临床意义.胃肠病学, 2007, 12(7):414-416.
10.	严茂军, 陆红梅, 孙庆旭, 等. RUNX3基因甲基化在结直肠癌发生中的作用及与预后的关系.中华普通外科杂志, 2012, 27(008):664-667.
11.	李华, 党荣良, 袁权利, 等.结肠癌组织中RUNX3, 突变型p53蛋白的表达变化及意义.山东医药, 2010, 50(026):56.
12.	肖开提, 阿不都, 哈德尔, 等.人结肠癌组织中RUNX3的表达意义.第四军医大学学报, 2008, 29(17):1618-1620.
13.	贾光辉, 薛军, 赵秀芳, 等. RUNX3和ki-67在结直肠癌中的表达及其相关性.内蒙古医学杂志, 2013, 45(5):524-528.
14.	Bangsow C, Rubins N, Glusman G, et al. The RUNX3 gene-sequence, structure and regulated expression. Gene, 2001, 279(2):221-232.
15.	张海元, 刘娟, 解庭波.肝细胞癌中RUNX3基因启动子区甲基化研究.华中科技大学学报:医学版, 2009, 38(1):23-26.
16.	Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Research, 2005, 65(11):4809-4816.
17.	Hiramatsu T, Osaki M, Ito Y, et al. Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology, 2006, 72(6):316-324.
18.	Shima K, Morikawa T, Baba Y, et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes & Control, 2011, 22(2):301-309.
19.	Imamura Y, Hibi K, Koike M, et al. RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer. Anticancer Res, 2005, 25(4):2627-2630.
20.	Ku JL, Kang SB, Shin YK, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene, 2004, 23(40):6736-6742.
21.	Peng Z, Tang H, Wang X, et al. Inhibition of the growth and metastasis of human colon cancer by restoration of RUNX3 expression in cancer cells. Int J Oncol, 2008, 33(5):979-984.
22.	何绍亚, 韩盛玺, 蒋仁发, 等. RUNX3基因甲基化及RUNX3蛋白表达在结肠癌发生中的意义.世界华人消化杂志, 2011, 19(17):1860-1863.
23.	Watanabe T, Kobunai T, Ikeuchi H, et al. RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol, 2011, 38(1):201-207.
24.	姜洪伟, 房学东, 张伟, 等.抑癌基因RUNX3基因在结直肠癌中的表达及临床意义.现代中西医结合杂志, 2011, 20(001):3-6.
25.	王蓓蓓. RUNX3蛋白在结直肠癌中的表达特点及意义.大连医科大学, 2011.
26.	Subramaniam MM, Chan JY, Soong R, et al. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am J Gastroenterol, 2009, 104(2):426-436.
27.	Soong R, Shah N, Peh B K, et al. The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Brit J Cancer, 2009, 100(5):676-679.
28.	肖述兵, 彭碧华, 万金龙, 等.原发性结肠癌组织RUNX3基因表达及临床意义.浙江临床医学, 2012, 14(7):775-776.

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA-Cancer J Clin, 2009, 59(4):225-249.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA-Cancer J Clin, 2011, 61(2):69-90.
3. 陈光侠, 何晓华, 陆敬华, 等.舒林酸对结肠癌SW1116细胞生长的影响.浙江临床医学, 2010, 12(1):3-6.
4. Lee Y M. Control of RUNX3 by histone methyltransferases. J Cell Biochem, 2011, 112(2):394-400.
5. Bosman F T, Cameiro F, Hruban R H, et al. World health organization classification of tumours of the digestive system. Lyon:IARC Press, 2010.
6. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 3rd Symposium on Systematic Reviews:Beyond the Basics. 2000.
7. 叶盛前, 叶菲, 金银姬, 等. RUNX3蛋白与Bcl-2家族蛋白在结肠癌中的表达及其意义.肿瘤学杂志, 2011, 17(12):893-896.
8. 汪砥, 钟美佐. RUNX3蛋白在大肠癌中的表达及其与临床化疗疗效关系探讨.肿瘤药学, 2011, 1(3):183-184.
9. 王殉, 王明林, 胡义奎. RUNX3蛋白在人结直肠癌中的表达及其临床意义.胃肠病学, 2007, 12(7):414-416.
10. 严茂军, 陆红梅, 孙庆旭, 等. RUNX3基因甲基化在结直肠癌发生中的作用及与预后的关系.中华普通外科杂志, 2012, 27(008):664-667.
11. 李华, 党荣良, 袁权利, 等.结肠癌组织中RUNX3, 突变型p53蛋白的表达变化及意义.山东医药, 2010, 50(026):56.
12. 肖开提, 阿不都, 哈德尔, 等.人结肠癌组织中RUNX3的表达意义.第四军医大学学报, 2008, 29(17):1618-1620.
13. 贾光辉, 薛军, 赵秀芳, 等. RUNX3和ki-67在结直肠癌中的表达及其相关性.内蒙古医学杂志, 2013, 45(5):524-528.
14. Bangsow C, Rubins N, Glusman G, et al. The RUNX3 gene-sequence, structure and regulated expression. Gene, 2001, 279(2):221-232.
15. 张海元, 刘娟, 解庭波.肝细胞癌中RUNX3基因启动子区甲基化研究.华中科技大学学报:医学版, 2009, 38(1):23-26.
16. Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Research, 2005, 65(11):4809-4816.
17. Hiramatsu T, Osaki M, Ito Y, et al. Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology, 2006, 72(6):316-324.
18. Shima K, Morikawa T, Baba Y, et al. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes & Control, 2011, 22(2):301-309.
19. Imamura Y, Hibi K, Koike M, et al. RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer. Anticancer Res, 2005, 25(4):2627-2630.
20. Ku JL, Kang SB, Shin YK, et al. Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines. Oncogene, 2004, 23(40):6736-6742.
21. Peng Z, Tang H, Wang X, et al. Inhibition of the growth and metastasis of human colon cancer by restoration of RUNX3 expression in cancer cells. Int J Oncol, 2008, 33(5):979-984.
22. 何绍亚, 韩盛玺, 蒋仁发, 等. RUNX3基因甲基化及RUNX3蛋白表达在结肠癌发生中的意义.世界华人消化杂志, 2011, 19(17):1860-1863.
23. Watanabe T, Kobunai T, Ikeuchi H, et al. RUNX3 copy number predicts the development of UC-associated colorectal cancer. Int J Oncol, 2011, 38(1):201-207.
24. 姜洪伟, 房学东, 张伟, 等.抑癌基因RUNX3基因在结直肠癌中的表达及临床意义.现代中西医结合杂志, 2011, 20(001):3-6.
25. 王蓓蓓. RUNX3蛋白在结直肠癌中的表达特点及意义.大连医科大学, 2011.
26. Subramaniam MM, Chan JY, Soong R, et al. RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am J Gastroenterol, 2009, 104(2):426-436.
27. Soong R, Shah N, Peh B K, et al. The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Brit J Cancer, 2009, 100(5):676-679.
28. 肖述兵, 彭碧华, 万金龙, 等.原发性结肠癌组织RUNX3基因表达及临床意义.浙江临床医学, 2012, 14(7):775-776.

Chinese Journal of Evidence-Based Medicine

Correlation between RUNX3 expression of Colorectal Cancer and Its Clinical Characteristics: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content